UroGen Pharma (URGN) Revenue (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Revenue data on file, last reported at $51.0 million in Q1 2026.

• Quarterly Revenue rose 151.6% year-over-year to $51.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.5 million (up 52.92% YoY) and the FY2025 annual result came in at $109.8 million, up 21.45% from the prior year.
• Revenue advanced to $51.0 million in Q1 2026, from $37.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $51.0 million in Q1 2026 to a low of $13.6 million in Q1 2022.
• A 5-year average of $23.4 million and a median of $21.1 million in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2024 — Revenue rose 3.35% — and 2026, when it jumped 151.6%.
• Tracing URGN's Revenue over 5 years: stood at $18.1 million in 2022, then jumped by 30.06% to $23.5 million in 2023, then gained by 4.4% to $24.6 million in 2024, then soared by 54.03% to $37.8 million in 2025, then surged by 34.68% to $51.0 million in 2026.
• The last three Revenue figures came in at $51.0 million (Q1 2026), $37.8 million (Q4 2025), and $27.5 million (Q3 2025), per Business Quant data.